K
Kell Østerlind
Researcher at Copenhagen University Hospital
Publications - 91
Citations - 5395
Kell Østerlind is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Lung cancer & Combination chemotherapy. The author has an hindex of 35, co-authored 90 publications receiving 5114 citations. Previous affiliations of Kell Østerlind include University of Copenhagen & Rigshospitalet.
Papers
More filters
Journal ArticleDOI
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
Jean Pierre Pignon,Rodrigo Arriagada,Daniel C. Ihde,David H. Johnson,Michael C. Perry,Robert L. Souhami,Ola Brodin,Rudolf A. Joss,Merrill S. Kies,Bernard Lebeau,Taisuke Onoshi,Kell Østerlind,Martin H.N. Tattersall,Henry Wagner +13 more
TL;DR: Thoracic radiotherapy moderately improves survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy, and identification of the optimal combination of chemotherapy and radiotherapy will require further trials.
Journal ArticleDOI
A procedure for measurement of distribution spaces in isolated fat cells.
TL;DR: Fat cells which had passed dinonyl phthalate exhibited normal lipogenesis from glucose and normal sensitivity to insulin, and 3H and 14C activity could be removed completely after washing of cells incubated with 3H2O and 3-O-[14C]methylglucose (40 mM).
Journal Article
Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue
Helle Pedersen,Nils Brünner,Dorthe Francis,Kell Østerlind,Ebbe Rønne,Heine H. Hansen,Keld Danø,Jan Grøndahl-Hansen +7 more
TL;DR: High uPAR was found to be an independent prognostic variable in squamous cell carcinoma patients, with a relative risk of 2.1 (95% confidence interval, 1.1-4.0) and tumor size the only other significant prognostic parameter.
Journal ArticleDOI
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.
TL;DR: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade, as well as long-term prognostic factors.
Journal ArticleDOI
Staging and prognostic factors in small cell lung cancer: a consensus report
R. Stahel,Robert J. Ginsberg,Klaus Havemann,Fred R. Hirsch,Daniel C. Ihde,Jacek Jassem,Karl Karrer,L. Herbert Maurer,Kell Østerlind,Paul Van Houtte +9 more
TL;DR: ‘Division of Oncology, Department of Medicine, University Hospital, Zitrich (Switzerland) and ‘ODepartment of Radiotherapy, Inrtitut Jules Bordet’.